US FDA Approves Novo Nordisk’s Ozempic to Cut Risk of Diabetic Kidney Disease Progression
The U.S. FDA has approved Novo Nordisk’s (NYSE: NVO) Ozempic for reducing the risk of kidney failure and disease progression, […]
Latest News on Novo Nordisk A/S (NVO) Stock
Novo’s Ozempic and Wegovy Picked for US Medicare Price Negotiations
Novo Nordisk’s (NYSE: NVO) blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare
Novo’s Ozempic and Wegovy Picked for US Medicare Price Negotiations Read More »
Novo Nordisk, Other Firms Meet Danish Prime Minister to Discuss Trump Tariff Threats
COPENHAGEN – Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby
Novo Nordisk, Other Firms Meet Danish Prime Minister to Discuss Trump Tariff Threats Read More »
Retail Investors Buy the Dip in Novo After Disappointing Weight-Loss Drug Data
U.S. retail investor fund flows into Novo Nordisk (NYSE: NVO) surged 32-fold on Friday, as the Danish drugmaker’s weaker-than-expected obesity
Retail Investors Buy the Dip in Novo After Disappointing Weight-Loss Drug Data Read More »
Novo Nordisk’s Drug Trial Results Weaken Danish Currency
COPENHAGEN – The Danish crown weakened on Friday after disappointing results from a late-stage trial of a new weight-loss drug
Novo Nordisk’s Drug Trial Results Weaken Danish Currency Read More »
Novo Nordisk (NYSE: NVO) Shares Plunge After CagriSema Obesity Drug Trial Results Disappoint
LONDON/COPENHAGEN – On Friday, Novo Nordisk (NYSE: NVO) revealed disappointing results in a late-stage trial for its experimental next-generation obesity
Novo Nordisk’s Dosing in CagriSema Obesity Drug Trial Puzzles Investors
LONDON/COPENHAGEN – On Friday, Novo Nordisk (NYSE: NVO) shareholders sought to find out why such a high number of patients
Novo Nordisk’s Dosing in CagriSema Obesity Drug Trial Puzzles Investors Read More »
In Weight Loss Battle, Novo and Lilly Face Growing Offensive from Licensed Copies
SHANGHAI – As Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) expand sales of their popular diabetes and weight-loss
In Weight Loss Battle, Novo and Lilly Face Growing Offensive from Licensed Copies Read More »
Novo Nordisk to Invest $1.2 Billion in New Rare Disease Drugs Plant in Denmark
STOCKHOLM/LONDON – Novo Nordisk (NYSE: NVO), the Danish drugmaker, will invest 8.5 billion crowns ($1.20 billion) in a new facility
Novo Nordisk to Invest $1.2 Billion in New Rare Disease Drugs Plant in Denmark Read More »
Lilly’s Mounjaro Gains Market Share Over Wegovy in UK’s Private Obesity Drug Market
LONDON – Britons paying privately for obesity drugs are increasingly choosing Eli Lilly’s (NYSE: LLY) Mounjaro over Novo Nordisk’s (NYSE:
Lilly’s Mounjaro Gains Market Share Over Wegovy in UK’s Private Obesity Drug Market Read More »
Novavax to Sell Czech Manufacturing Unit to Novo Nordisk for $200 Million
On Wednesday, Novavax (NASDAQ: NVAX), the U.S.-based vaccine maker, said it would sell its manufacturing facility in the Czech Republic
Novavax to Sell Czech Manufacturing Unit to Novo Nordisk for $200 Million Read More »
Novo, Lilly Shares Rise as Biden Proposes Obesity Care Coverage
COPENHAGEN – Shares of weight-loss drug makers Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) rose on Tuesday after
Novo, Lilly Shares Rise as Biden Proposes Obesity Care Coverage Read More »
Exclusive: Thousands Turn to Wegovy Copies Each Month as FDA Considers Shortage Status
More than 200,000 prescriptions for copies of Novo Nordisk’s (NYSE: NVO) weight-loss drug Wegovy are getting filled by U.S. patients
Exclusive: Thousands Turn to Wegovy Copies Each Month as FDA Considers Shortage Status Read More »
US Minority Veterans Face Unequal Access to Ozempic and Wegovy, Study Finds
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk’s (NYSE: NVO) highly in-demand drugs for diabetes
US Minority Veterans Face Unequal Access to Ozempic and Wegovy, Study Finds Read More »
Novo Nordisk CFO Forecasts High-Teens Sales Growth for 2025
LONDON – Novo Nordisk’s (NYSE: NVO) sales growth next year could be in the high teens in percentage terms, Chief
Novo Nordisk CFO Forecasts High-Teens Sales Growth for 2025 Read More »
Novo Nordisk Lifts Curbs on Wegovy Prescriptions in the US, CEO Says
COPENHAGEN – Novo Nordisk (NYSE: NVO) is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States
Novo Nordisk Lifts Curbs on Wegovy Prescriptions in the US, CEO Says Read More »
Novo Nordisk Stock Jumps as Q3 Wegovy Sales Top Estimates
COPENHAGEN – On Wednesday, Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug, reassuring investors worried that
Novo Nordisk Stock Jumps as Q3 Wegovy Sales Top Estimates Read More »
Novo Nordisk is Aware of 10 Deaths From Compounded Weight-Loss Drug Copies
LONDON – On Wednesday, Novo Nordisk (NYSE: NVO) chief financial officer Karsten Munk Knudsen said the company was aware of
Novo Nordisk is Aware of 10 Deaths From Compounded Weight-Loss Drug Copies Read More »
Americans Seeking Weight-Loss Drugs Face Supply and Insurance Hurdles
Americans are still eagerly seeking prescriptions for Eli Lilly’s (NYSE: LLY) and Novo Nordisk’s (NYSE: NVO) weight-loss and diabetes drugs
Americans Seeking Weight-Loss Drugs Face Supply and Insurance Hurdles Read More »
EU Regulators Set Deadline for Decision on Novo Holdings’ Catalent Acquisition
BRUSSELS/LONDON – EU antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer
EU Regulators Set Deadline for Decision on Novo Holdings’ Catalent Acquisition Read More »
US Medicaid Programs Say Cost a Key Factor for Weight-Loss Drug Coverage, Survey Finds
NEW YORK – Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk (NYSE: NVO) and
US Medicaid Programs Say Cost a Key Factor for Weight-Loss Drug Coverage, Survey Finds Read More »
Novo Nordisk’s Oral Diabetes Drug Reduces Heart-Related Risks by 14% in Study
On Monday, Novo Nordisk (NYSE: NVO) said an oral version of its drug semaglutide, helped significantly reduce the risk of
Novo Nordisk’s Oral Diabetes Drug Reduces Heart-Related Risks by 14% in Study Read More »
Consumer Groups Urge FTC to Block Novo Holdings-Catalent Deal
NEW YORK – On Thursday, U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission to
Consumer Groups Urge FTC to Block Novo Holdings-Catalent Deal Read More »
Novo Nordisk (NYSE: NVO) Bets Big on Talent and AI Partnerships in India
BENGALURU – Novo Nordisk (NYSE: NVO), whose global profile has risen along with demand for its Wegovy weight-loss drug, is
Novo Nordisk (NYSE: NVO) Bets Big on Talent and AI Partnerships in India Read More »
